BofA raised the firm’s price target on Ascendis Pharma (ASND) to $216 from $201 and keeps a Buy rating on the shares. The firm notes the company announced positive interim 26-week results for the phase 2 COACH trial evaluating combo treatment of QW TransCon CNP + QW TransCon hGH in achondroplasia children. The company guides to COACH 52-week data in Q4 that will be used to optimize the design of a phase 3 combo trial that will initiate in Q4. While BofA notes this is open label data, it views these results favorably as they suggest roughly 3-times better efficacy than TransCon CNP mono. The firm further thinks the update supports a clear differentiated efficacy profile in ACH in addition to weekly dosing that could help Ascendis capture more market share despite likely being 2nd to market. BofA highlights Ascendis as one of its top picks of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces interim analysis results from COACH trial
- Ascendis Pharma’s Promising Outlook: FDA Priority Review and Market Performance Drive Buy Rating
- Ascendis Pharma price target raised to $201 from $196 at BofA
- Ascendis Pharma’s TransCon CNP Receives FDA Priority Review
- FDA accepts Ascendis Pharma’s NDA for TransCon CNP for priority review